Is KOD a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Multi-indication Phase 3 pipeline, with revenue (ttm) at ~$0 (no approved products). The bear case rests on kodiak is still pre-revenue, and positive Phase 3 data does not guarantee FDA approval; the BLA has not yet been filed and a review typically takes about a year. Analysts covering it are spread from $103.00 to $145.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Kodiak is still pre-revenue, and positive Phase 3 data does not guarantee FDA approval; the BLA has not yet been filed and a review typically takes about a year. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $103.00, +20.1% from the $85.75 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Multi-indication Phase 3 pipeline. Kodiak has now delivered two positive Phase 3 programs. The most optimistic analyst target on KOD is $145.00, +69.1% from the $85.75 price. That figure is only reachable if this thesis works close to its best case.

Kodiak is still pre-revenue, and positive Phase 3 data does not guarantee FDA approval; the BLA has not yet been filed and a review typically takes about a year. The 2021 wet AMD failure is a reminder of how sharply the stock can move on a single event, and after a roughly 242% gain in 2026 the shares already price in a good deal of success (one valuation model cited in October headlines called them modestly overvalued). A first commercial launch would face entrenched competitors including Regeneron's Eylea franchise and Roche's Vabysmo, plus lower-cost off-label and biosimilar options. The company burns cash (net loss of about $66 million in Q2 2026, with cash of roughly $126 million at June 30), so additional dilutive financing is a realistic possibility. Ophthalmology commercialization is capital-intensive, and durability claims must hold up in real-world use to justify premium positioning. The most pessimistic published target is $103.00, +20.1% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Kodiak Sciences is a Palo Alto based biotechnology company developing therapies for high-prevalence retinal diseases such as diabetic retinopathy, wet age-related macular degenerat

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Multi-indication Phase 3 pipeline) stalling in the reported numbers rather than in the narrative, the risk above (kodiak is still pre-revenue, and positive Phase 3 data does not guarantee FDA approval; the BLA has not yet been filed and a review typically takes about a year) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Kodiak Sciences is a clinical-stage biotech developing treatments for retinal eye diseases such as diabetic retinopathy, wet AMD, and macular edema. Its candidates are built on an antibody biopolymer conjugate platform meant to make injections last longer between doses.

No. As of October 2026 Kodiak has no FDA-approved products and reports no product revenue. Its lead candidate, tarcocimab (Zenkuda), has positive Phase 3 data in diabetic retinopathy (GLOW2) and wet AMD (DAYBREAK), and Kodiak plans to submit a multi-indication BLA in Q4 2026, but it is not yet commercially available.

No. Kodiak operates at a loss because it has no product sales and spends heavily on research and development. It reported a net loss of about $66 million in Q2 2026 and roughly $242 million over the last twelve months, funded by cash on its balance sheet.